



NATIONAL QUALITY FORUM

Driving measurable health
improvements together

Memo

March 30, 2020

To: NQF members

From: NQF staff

Re: Commenting Draft Report: Cancer Review: Fall Cycle 2019

Background

This report reflects the review of measures in the Cancer project. The National Quality Forum's (NQF) portfolio of measures for cancer includes measures addressing cancer screening and appropriate cancer treatment (including surgery, chemotherapy, and radiation therapy).

The 19-person Cancer Standing Committee reviewed nine measures. Six were recommended for endorsement; and the Committee did not reach consensus for two of the measures and the vote was postponed on overall suitability for endorsement for one measure.

Recommended Measures:

- **NQF 0219** Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer
- **NQF 0220** Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB – Stage III hormone receptor positive breast cancer
- **NQF 0383** Oncology: Medical and Radiation - Plan of Care for Pain
- **NQF 1858** Trastuzumab administered to patients with AJCC stage I (T1c) – III human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy
- **NQF 1859** RAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy
- **NQF 1860** Patients with metastatic colorectal cancer and RAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies

Consensus Not Reached:

- **NQF 0223** Adjuvant chemotherapy is recommended, or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer
- **NQF 0384e** Oncology: Medical and Radiation - Pain Intensity Quantified

Vote Postponed – Overall Suitability for Endorsement:

- **NQF 0384:** Oncology: Medical and Radiation - Pain Intensity Quantified

The Committee requests comments on all measures, but specifically for the measures where consensus was not reached.

NQF Member and Public Commenting

NQF members and the public are encouraged to provide comments via the online commenting tool on the draft report as a whole, or on the specific measures evaluated by the Cancer Standing Committee.

Please note that commenting concludes on May 28, 2020 at 6:00 pm ET—no exceptions.

